Tarsus Pharmaceuticals (TARS) CHRO sells 15,565 shares via plan trade

Rhea-AI Filing Summary

Tarsus Pharmaceuticals’ Chief Human Resources Officer, Dianne C. Whitfield, reported automatic stock sales made under a pre-arranged Rule 10b5-1 trading plan. On January 2, 2026, she sold a total of 15,565 shares of Tarsus common stock in four transactions at weighted average prices ranging from about $80.09 to $82.93. The footnotes explain that each reported price is a weighted average for multiple individual trades, with actual prices spanning from $79.42 to $83.32. After these sales, she directly owned 23,393 shares of Tarsus common stock.

Insights

Insider trading and governance analyst

Pre-planned insider sales under a Rule 10b5-1 plan look routine and administrative.

Dianne C. Whitfield, Chief Human Resources Officer of Tarsus Pharmaceuticals, reported selling an aggregate of 15,565 shares of common stock on January 2, 2026. The sales were executed in four tranches at weighted average prices of about $80.09, $80.71, $81.90, and $82.93, and are classified with transaction code “S” for open-market or private sales.

A key detail is that the filing states these were automatic sales made pursuant to a Rule 10b5-1 trading plan adopted on September 12, 2025. Such plans allow insiders to schedule trades in advance, which can reduce concerns about trading on nonpublic information. The weighted average footnotes note that individual trade prices ranged between $79.42 and $83.32 across multiple executions.

Following the reported transactions, Whitfield directly held 23,393 shares of Tarsus common stock. The filing is focused on documenting these insider sales and the remaining direct holdings; actual implications for the company’s outlook depend on broader context beyond this single administrative disclosure.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Whitfield Dianne C.

(Last) (First) (Middle)

C/O TARSUS PHARMACEUTICALS, INC.

15440 LAGUNA CANYON ROAD, SUITE 160

(Street)

IRVINE CA 92618

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Tarsus Pharmaceuticals, Inc. [ TARS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Human Resources Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/02/2026		S(1)		5,715	D	$80.09(2)	33,243	D
Common Stock	01/02/2026		S(1)		8,122	D	$80.71(3)	25,121	D
Common Stock	01/02/2026		S(1)		835	D	$81.9(4)	24,286	D
Common Stock	01/02/2026		S(1)		893	D	$82.93(5)	23,393	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2025.

2. The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $79.42 to $80.40. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $80.42 to $81.29. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

4. The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $81.68 to $82.62. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

5. The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $82.82 to $83.32. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

	/s/ Jeffrey Farrow, Attorney-in-Fact	01/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who is the insider involved in this Form 4 for Tarsus Pharmaceuticals (TARS)?

The reporting person is Dianne C. Whitfield, who serves as Chief Human Resources Officer of Tarsus Pharmaceuticals, Inc..

How many Tarsus Pharmaceuticals (TARS) shares did the CHRO sell on January 2, 2026?

On January 2, 2026, Dianne C. Whitfield sold a total of 15,565 shares of Tarsus common stock in four separate transactions.

At what prices were the Tarsus (TARS) shares sold in this insider transaction?

The reported weighted average sale prices were about $80.09, $80.71, $81.90, and $82.93 per share, with individual trades occurring between $79.42 and $83.32.

Were the Tarsus (TARS) insider sales made under a Rule 10b5-1 plan?

Yes. The filing states the sales were automatic transactions made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 12, 2025.

How many Tarsus Pharmaceuticals (TARS) shares does the CHRO own after these sales?

After the reported transactions, Dianne C. Whitfield directly owned 23,393 shares of Tarsus Pharmaceuticals common stock.

Does this Form 4 disclose any derivative securities for Tarsus (TARS)?

No derivative securities transactions are reported in the completed portion of Table II; the detailed transactions disclosed are all in common stock.